BGNE BeiGene, Ltd.: Multiplikator Forward P/S
BeiGene, Ltd. (BGNE) leverages a broad presence across the US, Europe, and China to minimize regulatory risks. The professional management of John Euler ensures successful global expansion and financial stability. The brand's strong pricing power confirms its status as an oncology innovator. This chart of the company's projected P/S is available in the GURU.Markets system, where 5.50 determines the latest market demand valuation metric.
BeiGene, Ltd. - rincian analitis lan metrik utama (BGNE)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas BeiGene, Ltd.|BGNE - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal BeiGene Ltd|BGNE - Utang kumulatif perusahaan|Utang marang nilai buku BeiGene Ltd.|BGNE - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BeiGene|Indikator likuiditas cepet beigene.com
- rincian asil keuangan lan kelipatan valuasi:
BGNE - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep BeiGene, Ltd.|BGNE - Pangali rega marang bathi|Prakiraan rega marang bathi beigene.com|BGNE - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA BeiGene, Ltd.|BGNE - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) BeiGene|BGNE - Bathi resik saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan beigene.com|BGNE - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep BeiGene, Ltd.
- data pendapatan lan penerimaan dodolan:
Analisis wiwitan perusahaan:BeOne Medicines (BGNE)
The forward P/S ratio determines the market value of a business relative to expected revenue, allowing investors to assess the premium paid for future earnings without reporting delays. By analyzing the forward P/S trend, one can understand how BeiGene, Ltd. (BGNE) expenditures on environmental plant modernization and the implementation of green technologies impact the long-term capitalization and investment attractiveness of this biotech behemoth.
Pesaing wigati
Multiplikator Forward P/S ONC (BeiGene Oncology)|Multiplikator Forward P/S Halozyme Corp HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Group (AAPG) - Multiplikator forward rega marang pendapatan|CG Oncology Therapeutics (CGON) - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan UroGen Pharma URGN|Rasio rega marang prakiraan pendapatan Bicara Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Genomics PSNL|Multiplikator Forward P/S ERAS|Rasio rega marang pendapatan sing dikarepake DCTH|Y-mAbs Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Aura Biosciences Inc (AURA)|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc.)|SLS: Multiplikator Forward P/S|ACTU: Rasio rega marang pendapatan sing dikarepake|CTOR (Citius Oncology Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tuhurabio.com HURA|Multiplikator Forward P/S TARA|FATE: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S WHWK (Aadi Bioscience)|TCRX (TScan) - Rega mangsa ngarep marang pendapatan|Champions Oncology, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake XBiotech Inc XBIT|CVM: Multiplikator Forward P/S|OSTX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Radiopharm Theranostics Limited|Multiplikator Forward P/S artivabio.com|Multiplikator forward rega marang pendapatan ANL (Adlai Nortye Limited)|Veru - Kapitalisasi marang prakiraan pendapatan|Tempest Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake xiliotx.com (XLO)|Renovaro - Multiplikator Forward P/S|Mural Oncology (MURA) - Multiplikator forward rega marang pendapatan|KAPA: Multiplikator Forward P/S|OKUR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan CytoMed Therapeutics Limited|CRIS: Rega forward marang dodolan|Multiplikator Forward P/S APLM|Multiplikator Forward P/S tharimmune.com (THAR)|Advanced Biomed Corp - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan GNPX|Calidi Biotherapeutics, Inc. - Multiplikator Forward P/S|Sunshine Biopharma (SBFM) - Multiplikator forward rega marang pendapatan|XBIO: Multiplikator Forward P/S|SLRX - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PPBT|Multiplikator Forward P/S American Oncology Network|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|Multiplikator forward rega marang pendapatan Elevation Oncology, Inc. ELEV|Multiplikator Forward P/S ICAD (iCAD Inc.)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|viracta.com (VIRX) - Multiplikator forward rega marang pendapatan|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S
